摘要
To determine whether intravitreal bevacizumab could improve optical coherence tomography and visual acuity outcomes in a patient with neovascular age-related macular degenerationwho was responding poorly to pegaptanib therapy, an intravit real injection of bevacizumab (1.0 mg) was given. Within 1 week, optical coheren ce tomography revealed resolution of the subretinal fluid, resulting in a normal -appearing macular contour. The improved macular appearance was maintained for at least 4 weeks, and visual acuity remained stable. No inflammation was observe d. An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are l osing vision secondary to macular neovascularization.
To determine whether intravitreal bevacizumab could improve optical coherence tomography and visual acuity outcomes in a patient with neovascular age-related macular degenerationwho was responding poorly to pegaptanib therapy, an intravit real injection of bevacizumab (1.0 mg) was given. Within 1 week, optical coheren ce tomography revealed resolution of the subretinal fluid, resulting in a normal -appearing macular contour. The improved macular appearance was maintained for at least 4 weeks, and visual acuity remained stable. No inflammation was observe d. An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are l osing vision secondary to macular neovascularization.
出处
《世界核心医学期刊文摘（眼科学分册）》
2005年第11期38-38,共1页
Digest of the World Core Medical Journals:Ophthalmology
